A detailed history of Bridgeway Capital Management, LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 419,487 shares of VNDA stock, worth $2.14 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
419,487
Previous 437,963 4.22%
Holding current value
$2.14 Million
Previous $2.47 Million 20.49%
% of portfolio
0.04%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.61 - $6.34 $85,174 - $117,137
-18,476 Reduced 4.22%
419,487 $1.97 Million
Q2 2024

Aug 14, 2024

SELL
$3.91 - $6.5 $345,722 - $574,730
-88,420 Reduced 16.8%
437,963 $2.47 Million
Q1 2024

May 15, 2024

BUY
$3.47 - $4.61 $573,296 - $761,641
165,215 Added 45.74%
526,383 $2.16 Million
Q4 2023

Feb 14, 2024

SELL
$3.38 - $4.58 $919,059 - $1.25 Million
-271,911 Reduced 42.95%
361,168 $1.52 Million
Q3 2023

Nov 14, 2023

SELL
$4.28 - $6.57 $432,262 - $663,543
-100,996 Reduced 13.76%
633,079 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$5.9 - $6.95 $269,854 - $317,879
45,738 Added 6.64%
734,075 $4.84 Million
Q1 2023

May 15, 2023

BUY
$6.18 - $7.99 $2.24 Million - $2.9 Million
362,737 Added 111.41%
688,337 $4.67 Million
Q4 2022

Feb 14, 2023

BUY
$6.87 - $10.96 $2.24 Million - $3.57 Million
325,600 New
325,600 $2.41 Million
Q1 2022

May 16, 2022

SELL
$10.84 - $16.55 $1.74 Million - $2.65 Million
-160,300 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.69 - $21.14 $277,713 - $374,178
17,700 Added 12.41%
160,300 $2.52 Million
Q2 2021

Aug 16, 2021

BUY
$15.71 - $21.51 $2.24 Million - $3.07 Million
142,600 New
142,600 $3.07 Million

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $288M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.